3
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Race and ethnicity: Risk factors for fungal infections?

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Racial and ethnic identities, largely understood as social rather than biologic constructs, may impact risk for acquiring infectious diseases, including fungal infections. Risk factors may include genetic and immunologic differences such as aberrations in host immune response, host polymorphisms, and epigenomic factors stemming from environmental exposures and underlying social determinants of health. In addition, certain racial and ethnic groups may be predisposed to diseases that increase risk for fungal infections, as well as disparities in healthcare access and health insurance. In this review, we analyzed racial and ethnic identities as risk factors for acquiring fungal infections, as well as race and ethnicity as they relate to risk for severe disease from fungal infections. Risk factors for invasive mold infections such as aspergillosis largely appear related to environmental differences and underlying social determinants of health, although immunologic aberrations and genetic polymorphisms may contribute in some circumstances. Although black and African American individuals appear to be at high risk for superficial and invasive Candida infections and cryptococcosis, the reasons for this are unclear and may be related to underling social determinants of health, disparities in access to healthcare, and other socioeconomic disparities. Risk factors for all the endemic fungi are likely largely related to underlying social determinants of health, socioeconomic, and health disparities, although immunologic mechanisms likely play a role as well, particularly in disseminated coccidioidomycosis.

          Related collections

          Most cited references178

          • Record: found
          • Abstract: not found
          • Article: not found

          Mapping the Margins: Intersectionality, Identity Politics, and Violence against Women of Color

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.

            It is important to realize that guidelines cannot always account for individual variation among patients. They are not intended to supplant physician judgment with respect to particular patients or special clinical situations. IDSA considers adherence to these guidelines to be voluntary, with the ultimate determination regarding their application to be made by the physician in the light of each patient's individual circumstances.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium

              Mucormycosis is a difficult to diagnose rare disease with high morbidity and mortality. Diagnosis is often delayed, and disease tends to progress rapidly. Urgent surgical and medical intervention is lifesaving. Guidance on the complex multidisciplinary management has potential to improve prognosis, but approaches differ between health-care settings. From January, 2018, authors from 33 countries in all United Nations regions analysed the published evidence on mucormycosis management and provided consensus recommendations addressing differences between the regions of the world as part of the "One World One Guideline" initiative of the European Confederation of Medical Mycology (ECMM). Diagnostic management does not differ greatly between world regions. Upon suspicion of mucormycosis appropriate imaging is strongly recommended to document extent of disease and is followed by strongly recommended surgical intervention. First-line treatment with high-dose liposomal amphotericin B is strongly recommended, while intravenous isavuconazole and intravenous or delayed release tablet posaconazole are recommended with moderate strength. Both triazoles are strongly recommended salvage treatments. Amphotericin B deoxycholate is recommended against, because of substantial toxicity, but may be the only option in resource limited settings. Management of mucormycosis depends on recognising disease patterns and on early diagnosis. Limited availability of contemporary treatments burdens patients in low and middle income settings. Areas of uncertainty were identified and future research directions specified.
                Bookmark

                Author and article information

                Contributors
                Role: Editor
                Journal
                PLoS Pathog
                PLoS Pathog
                plos
                PLOS Pathogens
                Public Library of Science (San Francisco, CA USA )
                1553-7366
                1553-7374
                5 January 2023
                January 2023
                : 19
                : 1
                : e1011025
                Affiliations
                [1 ] Durham County Department of Public Health, Durham, North Carolina, United States of America
                [2 ] Division of Infectious Diseases, Department of Medicine, Duke University, Durham, North Carolina, United States of America
                [3 ] Department of Laboratory Medicine, National Institutes of Health, Bethesda, Maryland, United States of America
                [4 ] Department of Veterinary Pathology and Microbiology, University of Nigeria, Nsukka, Nigeria
                [5 ] Division of Infectious Diseases, Department of Medicine, University of Arizona, Tucson, Arizona, United States of America
                [6 ] Division of Infectious Diseases, Medical University of Graz, Graz, Austria
                [7 ] Department of Public Health Sciences, UC Davis School of Medicine, Davis, California, United States of America
                [8 ] Division of Infectious Diseases and Global Public Health, Department of Medicine, School of Medicine, University of California, San Diego, California, United States of America
                [9 ] University of California Davis Center for Valley Fever, Sacramento, California, United States of America
                [10 ] Department of Internal Medicine, Division of Infectious Diseases, University of California Davis Medical Center, Sacramento, California, United States of America
                [11 ] Department of Medical Microbiology and Immunology, University of California Davis, Davis, California, United States of America
                Rutgers University, UNITED STATES
                Author notes

                I have read the journal’s policy and the authors of this manuscript have the following competing interests: J.D.J. received research funding from Astellas, F2G, and Pfizer. M.M.A. received honoraria from Shionogi and La Jolla pharmaceuticals for participating in advisory board meetings. MH has received research funding from Gilead Sciences Europe Ltd, Astellas, Merck Sharp and Dohme, Scynexis, F2G, Euroimmune and Pfizer. G.R.T has received research grants and consultancy fees from Astellas, Amplyx, Cidara, and Mayne. All other authors declare no conflicts of interest.

                ‡ These authors are joint senior authors on this work.

                Author information
                https://orcid.org/0000-0001-6632-9587
                Article
                PPATHOGENS-D-22-01744
                10.1371/journal.ppat.1011025
                9815636
                36602962
                d3245f8c-89c6-4594-8dc2-ba65cfd39548
                © 2023 Jenks et al

                This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

                History
                Page count
                Figures: 1, Tables: 0, Pages: 22
                Funding
                The authors received no specific funding for this work.
                Categories
                Review
                Medicine and Health Sciences
                Epidemiology
                Medical Risk Factors
                Medicine and Health Sciences
                Medical Conditions
                Infectious Diseases
                Fungal Diseases
                People and places
                Population groupings
                Ethnicities
                African American people
                Medicine and Health Sciences
                Epidemiology
                Ethnic Epidemiology
                Medicine and Health Sciences
                Medical Conditions
                Infectious Diseases
                Fungal Diseases
                Coccidioidomycosis
                Medicine and Health Sciences
                Health Care
                Socioeconomic Aspects of Health
                Medicine and Health Sciences
                Public and Occupational Health
                Socioeconomic Aspects of Health
                Medicine and Health Sciences
                Epidemiology
                Medicine and Health Sciences
                Epidemiology
                Medical Risk Factors
                Cancer Risk Factors
                Medicine and Health Sciences
                Oncology
                Cancer Risk Factors

                Infectious disease & Microbiology
                Infectious disease & Microbiology

                Comments

                Comment on this article